BW 2258U89

Drug Profile

BW 2258U89

Alternative Names: 2258U89; BW 10; BW2258U89

Latest Information Update: 05 Jan 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antidepressants; Antineoplastics; Appetite stimulants; Oligopeptides
  • Mechanism of Action Bombesin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Eating disorders

Most Recent Events

  • 08 Jul 1998 No-Development-Reported for Cancer in United Kingdom (Unknown route)
  • 08 Jul 1998 No-Development-Reported for Eating disorders in United Kingdom (Unknown route)
  • 10 Nov 1995 Preclinical development for Cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top